Knowledge about hepatitis-C among methadone maintenance treatment patients in Israel

Substance Use and Misuse

Volumn 45, Issue 1-2, 2010, Pages 58-76

  Cohen Moreno, Rinat ^a,b   Schiff, Miriam ^a   Levitt, Shabtay ^b   Bar Hamburger, Rachel ^c   Strauss, Shiela ^d   Neumark, Yehuda ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Jerusalem Methadone Center   (Israel)

^c Israel Anti Drug Authority   (Israel)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Drug dependence; HCV; Hepatitis C; Knowledge; Methadone

Indexed keywords

ADULT; DRUG USERS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; ISRAEL; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS;

EID: 73649131591     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826080902864894     Document Type: Article

References (71)

1. Aceijas, C., Rhodes T. (2007). Global estimates of prevalence of HCV infection among injecting drug users. International Journal of Drug Policy, 18:352-358.
2. Astone-Twerell, J. M., Strauss, S. M., Hagan, H., Des Jarlais, D. C. (2005). Providing support to drug users infected with hepatitis C: The role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions, 3:33-46.
3. Backmund, M., Meyer, K., Von Zielonka, M., Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34:188-193.
4. Birkhead, G. S., Klein, S. J., Candelas, A. R., O'Connell, D. A., Rothman, J. R., Feldman, I. S., et al. (2007). Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach. International Journal of Drug Policy, 18:417-425.
5. Breslow, N. E., Day, N. E. (1980). Statistical methods in cancer research. Volume I: The analysis of case-control studies. Lyon: IARC Scientific Publications No 32.
6. Brown, R. S., Jr., Gaglio, P. J. (2003). Scope of worldwide hepatitis C problem. Liver Transplantation, 9:S10-S13.
7. Carey, J., Perlman, D. C., Friedmann, P., Kaplan, W. M., Nugent, A., Deutscher, M., et al. (2005). Knowledge of hepatitis among active drug injectors at a syringe exchange program. Journal of Substance Abuse Treatment, 29:47-53.
8. Centers for Disease Control and Prevention, Health People 2010- Immunization and Infectious Diseases. (2000). Retrieved April 6, 2008, from .ast;http://www.healthypeople.gov/document/html/volume1/14immunization.htm
9. Dhopesh, V. P., Taylor, K. R., Burke,W. M. (2000). Survey of hepatitis B and C in addiction treatment unit. American Journal of Drug and Alcohol Abuse, 26:703-707.
10. Doab, A., Treloar, C., Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(5 Suppl.):S313-S320.
11. Dore, G. J., Law, M., MacDonald, M., Kaldor, J. M. (2003). Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 26:171-184.
12. Deuffic-Burban, S., Poynard, T., Sulkowski, M. S., Wong, J. B. (2007). Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. Journal of Viral Hepatalogy, 14:107-115.
13. Deutsch,M., Hadziyannis, S. J. (2008). Old and emerging therapies in chronic hepatitis C: An update. Journal of Viral Hepatitis, 15:2-11.
14. D'Souza, R. F., Glynn, M. J., Alstead, E., Osonayo, C., Foster, G. R. (2004). Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. QJM, 97:331-336.
15. Edlin, B. R., Kresina, T. F., Raymond, D. B., Carden, M. R., Gourevitch, M. N., Rich, J. D., et al. (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases, 40(5 Suppl.):S276-S285.
16. Fischer, B., Kalousek, K., Rehm, J., Powis, J., Krajden, M., Reimer, J. (2006). Hepatitis C, illicit drug use and public health: Does Canada really have a viable plan? Canadian Journal of Public Health, 97:485-488.
17. Fishbein, D. A., Lo, Y., Reinus, J. F., Gourevitch, M. N., Klein, R. S. (2004). Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndromes, 37:1367-1375.
18. Fisher, J. D., Fisher, W. A. (1992). Changing AIDS-risk behavior. Psychological Bulletin, 111:455-474.
19. Fried, M.W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347:975-982.
20. Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showler, G., et al. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93:141-147.
21. Gyarmathy, V. A., Neaigus, A., Miller, M., Friedman, S. R., Des Jarlais, D. C. (2002). Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. Journal of Acquired Immune Deficiency Syndromes, 30:448-456.
22. Hagan, H., Strauss, S. M., Astone, J. M., Des Jarlais, D. C. (2005). Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clinical Infectious Diseases, 40(5 Suppl.):S297-S303.
23. Hagedorn, H.,Dieperink, E.,Dingmann, D.,Durfee, J.,Ho, S. B., Isenhart,C., et al. (2007). Integrating hepatitis prevention services into a substance use disorder clinic. Journal of Substance Abuse Treatment, 32:391-398.
24. Hallinan, R., Byrne, A., Agho, K., Dore, G. J. (2007). Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence, 88:49-53.
25. Hallinan, R., Byrne, A., Amin, J., Dore, G. J. (2005). Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of Gastroenterology and Hepatology, 20:1082-1086.
26. Health Canada, Hepatitis C - Final Report. Angus Reid Group. (2000). Retrieved April 6, 2008, from http://www.phac-aspc.gc.ca/hepc/pubs/fr-rf00/pdf/ careDiscSurvey.pdf.
27. Heimer, R., Clair, S., Grau, L. E., Bluthenthal, R. N., Marshall, P. A., Singer, M. (2002). Hepatitisassociated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97:1277-1287.
28. Hu, S. W., Lai, H. R., Liao, P. H. (2004). Comparing dental students' knowledge of and attitudes toward hepatitis B virus-, hepatitis C virus-, and HIV-infected patients in Taiwan. AIDS Patient Care and STDs, 18:587-593.
29. Khuwaja, A. K., Qureshi, R., Fatmi, Z. (2002). Knowledge about hepatitis B and C among patients attending family medicine clinics in Karachi. Eastern Mediterranean Health Journal, 8:787-793.
30. Kwiatkowski, C. F., Fortuin Corsi, K., Booth, R. E. (2002). The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction, 97:1289-1294.
31. Law, M. G., Dore, G. J., Bath, N., Thompson, S., Crofts, N., Dolan, K., et al. (2003). Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 32:717-724.
32. Litwin, A. H., Soloway, I., Gourevitch, M. N. (2005). Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases, 40(5 Suppl.):S339-S345.
33. Loguercio, C., Di Pierro, M., Di Marino, M. P., Federico, A., Disalvo, D., Crafa, E., et al. (2000). Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol and Alcoholism, 35:296-301.
34. Mauss, S., Berger, F., Goelz, J., Jacob, B., Schmutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40:120-124.
35. McCarthy, J. J., Flynn, N. (2001). Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. Journal of Addictive Diseases, 20:19-31.
36. Mehta, S. H., Thomas, D. L., Sulkowski, M. S., Safaein, M., Vlahov, D., Strathdee, S. A. (2005). A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS, 19(3 Suppl.):S179-S189.
37. Memon, M. I., Memon, M. A. (2002). Hepatitis C: An epidemiological review. Journal of Viral Hepatitis, 9:84-100.
38. Morrow, K., Costello, T. (2004). HIV, STD and hepatitis prevention among women in methadone maintenance: A qualitative and quantitative needs assessment. AIDS Care, 16:426-433.
39. Munoz-Plaza, C. E., Strauss, S. M.,Astone, J.M., Des Jarlais, D. C., Hagan,H. (2004).Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues, 34:861-878.
40. Munoz-Plaza, C. E., Strauss, S. M., Astone-Twerwll, J. M., Des Jarlais, D. C., Hagan, H. (2006). Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs. Journal of Psychoactive Drugs, 38:233-241.
41. Novick, D.M. (2000). The impact of hepatitis C virus infection onmethadone maintenance treatment. The Mount Sinai Journal of Medicine, 67:437-443.
42. Ompad, D. C., Fuller, C. M.,Vlahov, D., Thomas, D., Strathdee, S. A. (2002). Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clinical Infectious Diseases, 35:783-788.
43. Peles, E., Schreiber, S., Adelson, M. (2006). Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug and Alcohol Dependence, 82:211-217.
44. Quaglio, G., Lugoboni, F., Pajusco, B., Sarti, M., Talamini, G., Lechi, A., et al. (2003). Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clinical Infectious Diseases, 37:33-40. (Pubitemid 36836642)
45. Reynolds, G. L., Fisher, D. G., Jaffe, A., Edwards, J. (2006). Follow-up for medical care among drug users with hepatitis C. Evaluation & the Health Professions, 29:355-366.
46. Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldberg, D.,Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection, 129:577-585.
47. Sastre, M. T., Monsirmen, S., Morin, G., Presutto, E., Seguela, L., Vinel, J.-P., et al. (2006). Changes in French people's misconceptions about hepatitis C, 1997-2003. Preventive Medicine, 42:150-153.
48. Schaefer, M., Heinz, A., Backmund, M. (2004). Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction, 99:1167-1175.
49. Scheinmann, R., Hagan, H., Lelutiu-Weinberger, C., Stern, R., Des Jarlais, D. C., Flom, P. L., et al. (2007). Non-injection drug use and Hepatitis C Virus: A systematic review. Drug and Alcohol Dependence, 89:1-12.
50. Schiff, M., Levit, S., Moreno, R. C. (2007). Retention and illicit drug use among methadone patients in Israel: A gender comparison. Addictive Behaviors, 32:2108-12019
51. Seeff, L. B., Hoofnagle, J. H. (2003). Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clinics in Liver Disease, 7:261-287.
52. Sergio, N., Salvatore, T., Gaetano, B., Davide, P., Claudio, I., Massimo, L., et al. (2007). Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin. Journal of Gastroenterology and Hepatology, 22:74-79.
53. Shackman, B. R., Teixeira, P. A., Beeder, A. B. (2007). Offers of hepatitis C care do not lead to treatment. Journal of Urban Health, 84:455-458.
54. Shepard, C. W., Finelli, L., Alter, M. J. (2005). Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases, 5:558-567.
55. Stein, M. D.,Maksad, J.,Clarke, J. (2001). HepatitisCdisease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence, 61:211-215.
56. Stephenson, J. (2001). Former addicts face barriers to treatment for HCV. JAMA, 285:1003-1005.
57. Stoov́e, M. A., Gifford, S.M., Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 77:81-86.
58. Strathdee, S. A., Latka, M., Campbell, J., O'Driscoll, P. T., Golub, E. T., Kapadia, F., et al. (2005). Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(5 Suppl.):S304-S312.
59. Strauss, S. M., Astone, J. M., Hagan, H., Des Jarlais, D. C. (2004a). The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. Journal of Urban Health, 81:38-47.
60. Strauss, S. M., Astone, J. M., Jarlais, D. D., Hagan, H. (2004b). A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence, 73:227-236.
61. Strauss, S. M., Astone, J.M., Munoz-Plaza, C., Hagan, H., Des Jarlais, D. C. (2005). Residential drug treatment programs as venues for HCV pharmacological treatment: Client and staff perspectives. Substance Use and Misuse, 40:1811-1829.
62. Strauss, S. M., Astone-Twerell, J. M., Munoz-Plaza, C., Des Jarlais, D. C., Gwadz, M., Hagan, H., et al. (2006). Hepatitis C knowledge among staff in U.S. drug treatment programs. Journal of Drug Education, 36:141-158.
63. Strauss, S. M., Astone-Twerell, J., Munoz-Plaza, C. E., Des Jarlais, D. C., Gwadz, M., Hagan, H., et al. (2007). Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research, 7:39.
64. Strauss, S. M., Falkin, G. P., Vassilev, Z., Des Jarlais, D. C., Astone, J. (2002). A nationwide survey of hepatitisCservices provided by drug treatment programs. Journal of Substance Abuse Treatment, 22:55-62.
65. Sulkowski, M. S., Thomas, D. L. (2005). Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clinical Infectious Diseases, 40(5 Suppl.):S263-S269.
66. Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug and Alcohol Dependence, 67:117-123.
67. Tortu, S., Neaigus, A., McMahon, J., Hagen, D. (2001). Hepatitis C among noninjecting drug users: A report. Substance Use & Misuse, 36:523-534.
68. van den Berg, C. H., Smit, C., Bakker, M., Geskus, R. B., Berkhout, B., Jurriaans, S., et al. (2007). Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology, 22:183-193.
69. Vidal-Tŕecan, G., Coste, J., Varescon-Pousson, I., Christoforov, B., Boissonnas, A. (2000). HCV status knowledge and risk behaviours amongst intravenous drug users. European Journal of Epidemiology, 16:439-445.
70. Walley, A. Y., White, M. C., Kushel, M. B., Song, Y. S., Tulsky, J. P. (2005). Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 28:181-1877.
71. Winstock, A. R., Sheridan, J., Lovell, S., Farrell, M., Strang, J. (2000). National survey of hepatitis testing and vaccination services provided by drug services in England and Wales. European Journal of Clinical Microbiology & Infectious Diseases, 19:823-828.